Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,265
archived clinical trials in
Crohns Disease

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Univ of North Carolina
mi
from
Chapel Hill, NC
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Clinical Trials Of America, Inc.
mi
from
Winston Salem, NC
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Clinical Trials Of America, Inc.
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Consultants for Clinical Research Inc.
mi
from
Cincinnati, OH
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Consultants for Clinical Research Inc.
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
The Ohio State University-Inflammatory Bowel Disease Ctr
mi
from
Columbus, OH
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
The Ohio State University-Inflammatory Bowel Disease Ctr
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Great Lakes Gastroenterology
mi
from
Mentor, OH
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Great Lakes Gastroenterology
mi
from
Mentor, OH
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Gastroenterology United of Tulsa
mi
from
Tulsa, OK
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Gastroenterology United of Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Northwest Gastroenterology Clinic, LLD
mi
from
Portland, OR
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Northwest Gastroenterology Clinic, LLD
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
James J. Boylan Gastroenterology and Liver Diseases
mi
from
Bethlehem, PA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
James J. Boylan Gastroenterology and Liver Diseases
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Shirish A. Amin, MD, PC
mi
from
Indiana, PA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Shirish A. Amin, MD, PC
mi
from
Indiana, PA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Donald Guthrie Foundation for Education and Research
mi
from
Sayre, PA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Donald Guthrie Foundation for Education and Research
mi
from
Sayre, PA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Cherry Tree Medical
mi
from
Uniontown, PA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Cherry Tree Medical
mi
from
Uniontown, PA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Omega Medical Research
mi
from
Warwick, RI
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Omega Medical Research
mi
from
Warwick, RI
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Vanderbilt University Medical Center
mi
from
Nashville, TN
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Lovelace Scientific Resources, Inc.
mi
from
Austin, TX
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Lovelace Scientific Resources, Inc.
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Austin Gastroenterology PA/Professional Quality Research, Inc.
mi
from
Austin, TX
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Austin Gastroenterology PA/Professional Quality Research, Inc.
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Diagnostic Clinic of Houston
mi
from
Houston, TX
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Diagnostic Clinic of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Baylor College of Medicine
mi
from
Houston, TX
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Gastroenterology Associates of Northern Virginia
mi
from
Fairfax, VA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Gastroenterology Associates of Northern Virginia
mi
from
Fairfax, VA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
VCU Medical Center
mi
from
Richmond, VA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  2/22/2013
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 2/22/2013
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease
Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease
Status: Enrolling
Updated:  3/12/2013
Santa Barbara Cottage Hospital
mi
from
Santa Barbara, CA
Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease
Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease
Status: Enrolling
Updated: 3/12/2013
Santa Barbara Cottage Hospital
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Glendale, AZ
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Anaheim, CA
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Aurora, CO
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
New Haven, CT
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Jacksonville, FL
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Roswell, GA
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Roswell, GA
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Joliet, IL
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Joliet, IL
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Indianapolis, IN
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Louisville, KY
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Baton Rouge, LA
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Bethesda, MD
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Boston, MA
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Grand Rapids, MI
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Rochester, MN
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Jackson, MS
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Jackson, MS
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Chesterfield, MO
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Chesterfield, MO
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Exeter, NH
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Exeter, NH
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Cherry Hill, NJ
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
New York, NY
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Durham, NC
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Cincinnati, OH
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Weatherford, OK
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Weatherford, OK
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Klamath Falls, OR
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Klamath Falls, OR
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Knoxville, TN
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Austin, TX
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
GSK Investigational Site
mi
from
Kennewick, WA
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
GSK Investigational Site
mi
from
Kennewick, WA
Click here to add this to my saved trials
Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease
A Phase III, Randomized, Double-blind Trial in the Comparison of Cimzia Versus Cimzia Plus Azathioprine in the Change in Mean SES-CD (Simple Endoscopic Scores-Crohn's Disease) Scores in the Treatment of Active, Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  3/21/2013
Gastroenterology Research of America
mi
from
San Antonio, TX
Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease
A Phase III, Randomized, Double-blind Trial in the Comparison of Cimzia Versus Cimzia Plus Azathioprine in the Change in Mean SES-CD (Simple Endoscopic Scores-Crohn's Disease) Scores in the Treatment of Active, Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 3/21/2013
Gastroenterology Research of America
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy
Status: Enrolling
Updated:  3/26/2013
Clinical Research Facility
mi
from
Mobile, AL
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy
Status: Enrolling
Updated: 3/26/2013
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials